BerGenBio ASA (BRRGF) Stock Price, News & Analysis

Company Overview

BerGenBio ASA is a clinical‐stage biopharmaceutical company developing novel therapies that target the AXL signaling pathway to address unmet medical needs in oncology and fibrotic diseases. The company’s proprietary platform is built around AXL, a receptor tyrosine kinase implicated in tumor progression, metastasis and treatment resistance, as well as in the development of fibrosis across multiple organ systems.

The company’s lead product candidate, bemcentinib (BGB324), is a first‐in‐class, selective AXL inhibitor being evaluated in multiple clinical trials for indications such as non‐small cell lung cancer, acute myeloid leukemia and mesothelioma. Bemcentinib has also been studied in combination with standard therapies and immune‐modulating agents. In addition to bemcentinib, BerGenBio’s pipeline includes BGB149, a monoclonal antibody designed to block AXL activity in fibrotic diseases, currently advancing through preclinical development.

Founded in 2013 as a spin‐out from the University of Bergen, BerGenBio is headquartered in Bergen, Norway, with research and clinical operations extending into the United Kingdom and the United States. The company collaborates with leading academic institutions, contract research organizations and regulatory agencies to design and execute its development programs. BerGenBio’s integrated research, regulatory and clinical teams work together to move candidates from discovery through late‐stage clinical validation.

Under the leadership of Chief Executive Officer Richard Godfrey, BerGenBio is focused on translating its AXL expertise into therapies that can improve outcomes for patients with serious and life-threatening diseases. The company continues to expand its portfolio by exploring additional indications for AXL inhibition and forging strategic partnerships to accelerate global development and commercialization efforts.

Key Stats

• Today's Range: $250.00 to $250.00
• 50-Day Range: $250.00 to $250.00
• 52-Week Range: $0.03 to $0.03
• Volume: N/A
• Average Volume: 200 shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

BRRGF Stock Analysis - Frequently Asked Questions

How have BRRGF shares performed this year?

BerGenBio ASA's stock was trading at $2.50 at the beginning of 2025. Since then, BRRGF shares have increased by 9,900.0% and is now trading at $250.00.

How do I buy shares of BerGenBio ASA?

Shares of BRRGF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: N/A
• Current Symbol: OTCMKTS:BRRGF
• CIK: N/A
• Web: www.bergenbio.com
• Phone: 47 53 50 15 64
• Fax: N/A
• Employees: 18
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A